Recombinant Human EphA1 Fc Chimera Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human EphA1 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human EphA1 Fc Chimera is coated at 2 μg/mL (100 μL/well), the concentration of Biotinylayed Recombinant Mouse Ephrin‑A1 Fc Chimera (Catalog # BT602) that produces 50% of the optimal binding response is typically 10-50 ng/mL.
• Source: Human embryonic kidney cell, HEK293-derived human EphA1 protein
  

  Human EphA1 (Met1-Glu547) Accession # AAA36747	DIEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: AAA36747
• N-terminal Sequence: Lys26
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: EPHA1
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <0.01 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 83.5 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 100-110 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after opening.
  • 3 months, -20 to -70 °C under sterile conditions after opening.
• Buffer: Supplied as a 0.2 μm filtered solution in MES, NaCl, PEG 3350, CHAPS and Imidazole.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human EphA1 Fc Chimera Protein, CF

• EC 2.7.10
• EC 2.7.10.1
• EPH receptor A1
• eph tyrosine kinase 1
• EphA1
• EPHephrin type-A receptor 1
• EPHT
• EPHT1erythropoietin-producing hepatoma amplified sequence
• Esk
• MGC163163
• oncogene EPH
• soluble EPHA1 variant 1
• soluble EPHA1 variant 2
• Tyrosine-protein kinase receptor EPH

Background

EphA1, also known as Eph and Esk, is a 120‑130 kDa glycosylated member of the Eph family of transmembrane receptor tyrosine kinases. The A and B classes of Eph proteins are distinguished by Ephrin ligand binding preference but have a common structural organization. Eph‑Ephrin interactions are widely involved in the regulation of cell migration, tissue morphogenesis, and cancer progression (1‑3). Mature mouse EphA1 consists of a 524 amino acid (aa) extracellular domain (ECD), a 21 aa transmembrane segment, and a 408 aa cytoplasmic domain. The ECD contains an N-terminal globular domain, a cysteine-rich domain, and two fibronectin type III domains. The cytoplasmic domain contains a juxtamembrane motif with two tyrosine residues which are the major autophosphorylation sites, a kinase domain, and a conserved sterile alpha motif (SAM) (4). Within the ECD, human EphA1 shares 84% aa sequence identity with mouse and rat EphA1. EphA1 can form pH sensitive cis-homodimers on the cell surface (5). Membrane-bound or clustered Ephrin ligands interact with EphA1 and activate its kinase domain which is capable of Ser, Thr, and Tyr phosphorylation (6). Reverse signaling is propagated through the Ephrin ligand (7). EphA1 is widely expressed in differentiated epithelial cells, particularly in bone marrow, spleen, thymus, and testes (6, 8). It is additionally expressed on CD4⁺ T cells and a subpopulation of CD19⁺ B cells (9, 10). On CD4⁺ T cells, EphA1 interacts with EphA4, induces Tyr phosphorylation of PYK2, and promotes chemokine-induced chemotaxis (9, 10). EphA1 is up‑regulated or down‑regulated in a variety of human carcinomas and is implicated in tumor invasiveness (3, 7, 11). The region of Fibronectin including type I repeats #10‑12 interacts with EphA1, and this interaction plays a role in VEGF-dependent in vitro angiogenesis (12).

1. Poliakov, A. et al. (2004) Dev. Cell 7:465.
2. Miao, H. and B. Wang (2009) Int. J. Biochem. Cell Biol. 41:762.
3. Mosch, B. et al. (2010) J. Oncol. Mar 10 Epub.
4. Hirai H. et al. (1987) Science 238:1717.
5. Bocharov, E.V. et al. (2008) J. Biol. Chem. 283:29385.
6. Douville, E.M.J. et al. (1992) Mol. Cell. Biol. 12:2681.
7. Pasquale, E.B. (2010) Nat. Rev. Cancer 10:165.
8. Coulthard, M.G. et al. (2001) Growth Factors 18:303.
9. Aasheim, H.-C. et al. (2005) Blood 105:2869.
10. Holen, H.L. et al. (2010) J. Leukoc. Biol. 87:1059.
11. Dong, Y. et al. (2009) Mod. Pathol. 22:151.
12. Masuda, J. et al. (2008) J. Biol. Chem. 283:13148.

Publications for EphA1 (7146-A1)(2)

Publications using 7146-A1

• JH Cha, LC Chan, YN Wang, YY Chu, CH Wang, HH Lee, W Xia, WC Shyu, SP Liu, J Yao, CW Chang, FR Cheng, J Liu, SO Lim, JL Hsu, WH Yang, GN Hortobagyi, C Lin, L Yang, D Yu, LB Jeng, MC Hung Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer The Journal of Biological Chemistry, 2022-03-10;0(0):101817. 2022-03-10 [PMID: 35278434] (ELISA Capture, N/A)
• Ieguchi K, Tomita T, Omori T, Komatsu A, Deguchi A, Masuda J, Duffy S, Coulthard M, Boyd A, Maru Y ADAM12-cleaved ephrin-A1 contributes to lung metastasis. Oncogene, 2013-05-20;33(17):2179-90. 2013-05-20 [PMID: 23686306] (In Vivo, Mouse)

Bioinformatics

• Gene Symbol: EPHA1
• Uniprot:
  • AAA36747()